Prostate Cancer Treatment Without Surgery: Options and When They May Be Used

A diagnosis of prostate cancer does not automatically mean that the prostate must be surgically removed.

For some men, surgery is an appropriate treatment. For others, radiation therapy, active surveillance, hormone-based treatment or another non-surgical approach may be more suitable. This guide sits beside the Prostate Cancer Treatment in India pathway and the treatment-options explainer.

The choice depends on the biology and extent of the cancer.

Doctors commonly look at:

The American Cancer Society notes that treatment decisions also depend on the cancer's risk group, age, overall health, life expectancy and personal preferences.

This is why two men with prostate cancer can receive completely different treatment plans. International patients comparing centres often start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

The phrase can describe several very different approaches.

Some treatments are intended to control or eliminate the cancer.

Others are designed to monitor the cancer and delay treatment until it shows signs of progression.

It helps to separate them into three broad categories.

These treatments are not interchangeable.

The appropriate option depends on whether the cancer is low-risk, intermediate-risk, high-risk, locally advanced or metastatic.

Active surveillance is one of the most important non-surgical approaches for prostate cancer.

It is mainly used for men whose cancer appears unlikely to cause problems in the near term.

Instead of treating the cancer immediately, doctors monitor it closely.

If the cancer shows evidence of becoming more aggressive, definitive treatment can then be considered.

The monitoring programme may include:

The exact schedule differs between patients and treatment protocols.

The American Cancer Society describes active surveillance as close monitoring, often involving PSA testing approximately every 3–6 months, periodic examination and, in selected patients, repeat imaging or biopsy.

Active surveillance is commonly considered for:

It is generally more appropriate when the cancer is:

The American Cancer Society notes that active surveillance is typically recommended for very-low-risk disease and is commonly offered to men with low-risk disease. It can also be considered in selected favorable intermediate-risk cases.

No.

This is one of the most common misunderstandings.

Active surveillance is a structured medical programme.

The patient continues to be monitored for signs that the cancer is becoming more aggressive.

If those signs appear, treatment can be started.

The objective is to avoid unnecessary treatment while maintaining the opportunity for curative treatment if the cancer progresses.

Watchful waiting is different from active surveillance.

The terms are sometimes used interchangeably in everyday conversation, but they represent different strategies.

The intention is to identify cancer progression early enough to provide curative treatment if necessary.

The approach is generally less intensive.

The focus is on monitoring the patient's health and treating symptoms if they develop.

Watchful waiting is more commonly considered for older men or men with significant other health conditions where immediate curative treatment may offer limited benefit.

The NCI distinguishes active surveillance from watchful waiting in this way: active surveillance aims to detect progression and begin treatment with curative intent, while watchful waiting generally focuses on symptoms and quality of life.

Radiation therapy is one of the most established alternatives to prostatectomy.

Unlike surgery, the prostate is not removed.

Instead, high-energy radiation is used to damage and destroy cancer cells.

Radiation can be used:

The American Cancer Society identifies external beam radiation and brachytherapy as established radiation treatments for prostate cancer.

External beam radiation therapy, or EBRT, delivers radiation from a machine outside the body.

The radiation is carefully planned to target the prostate while limiting exposure to surrounding tissues.

Modern techniques include:

The exact technique depends on the patient's disease and the radiation centre. Radiation oncologists in India plan the dose after reviewing PSA, Grade Group and imaging.

Intensity-modulated radiation therapy (IMRT) allows radiation intensity to be adjusted across different parts of the treatment field.

This helps the radiation oncology team shape the dose around the prostate.

Treatment is generally delivered over multiple sessions.

Image-guided radiation therapy (IGRT) uses imaging during treatment to improve positioning and targeting.

This is particularly useful because the prostate can move slightly relative to nearby organs.

Volumetric modulated arc therapy (VMAT) delivers radiation while the treatment machine rotates around the patient.

It can allow individual treatment sessions to be completed relatively quickly.

Stereotactic body radiation therapy (SBRT) delivers a higher dose of radiation during each session.

As a result, the complete treatment course can be completed in substantially fewer sessions than conventional radiation.

The American Cancer Society notes that SBRT can deliver the complete course over several days for selected patients.

Not every patient is automatically suitable for SBRT.

Patient selection depends on factors such as cancer characteristics, prostate anatomy, urinary function and the treating radiation oncologist's assessment.

Brachytherapy is another non-surgical treatment option.

Instead of directing radiation from outside the body, radioactive material is placed directly inside or close to the prostate.

There are two major approaches:

Small radioactive seeds are placed inside the prostate.

The seeds release radiation over time.

A radioactive source is temporarily inserted into the prostate through specially positioned applicators.

The radiation is delivered over a shorter period and the source is then removed.

Brachytherapy can be used in selected men with localized prostate cancer.

It may be used alone for certain lower-risk cancers.

For some higher-risk cancers, it may be combined with external beam radiation and hormone therapy.

The American Cancer Society notes that brachytherapy alone is generally used for selected early-stage, lower-risk disease, while combination approaches may be considered for higher-risk cancers.

See brachytherapy cost in India for the current GAF planning range.

Hormone therapy is also known as androgen deprivation therapy (ADT).

Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, for growth.

Hormone therapy reduces androgen production or blocks androgen activity.

It does not physically remove the prostate.

Hormone therapy may be used:

For higher-risk localized or locally advanced disease, hormone therapy may be combined with radiation.

For metastatic disease, it is often part of systemic treatment.

The NCI notes that hormone therapy can delay progression of metastatic disease and may extend survival, but it also has important potential side effects.

Hormone-therapy doctors and the India cost sheet help international patients compare programmes.

It depends on the situation.

Hormone therapy alone is not generally the preferred definitive treatment for localized prostate cancer in otherwise suitable patients.

The American Cancer Society notes that hormone therapy is generally not recommended as the sole treatment for early-stage prostate cancer because studies have not shown a survival advantage over observation or active surveillance in that setting.

However, hormone therapy has an important role in:

This distinction is important when searching online for “prostate cancer treatment without surgery.”

Modern prostate cancer treatment is not limited to traditional hormone injections.

Several medicines target the androgen-signalling pathway more directly.

Examples include:

These medicines may be used in selected patients with advanced or high-risk prostate cancer.

They are generally used according to the stage, disease biology and treatment history.

The treatment may also be combined with androgen deprivation therapy.

For this reason, “hormone therapy” can mean different things depending on the patient's disease.

Chemotherapy is another non-surgical treatment.

It uses medicines that circulate through the body and attack rapidly dividing cancer cells.

For prostate cancer, chemotherapy is generally more relevant to advanced or metastatic disease than to low-risk localized cancer.

A commonly used chemotherapy drug is docetaxel.

Other chemotherapy medicines may be considered depending on the treatment setting.

Chemotherapy may be combined with hormone therapy in selected patients with metastatic disease.

It is not normally the first treatment for a small, low-risk prostate cancer confined to the prostate.

See chemotherapy cost in India and medical oncologists.

Targeted therapy is designed to exploit specific characteristics of cancer cells.

One important example in advanced prostate cancer is treatment with PARP inhibitors.

These drugs may be appropriate for selected patients whose cancer has particular genetic or molecular alterations involving DNA-repair pathways.

Examples include alterations involving genes such as:

This is why molecular testing can become relevant in advanced prostate cancer.

Not every patient will benefit from targeted therapy.

Targeted-therapy cost in India varies with the medicine and duration.

Radiopharmaceutical treatment is an important area of modern prostate cancer care.

These medicines contain a radioactive component that is linked to a molecule capable of targeting cancer cells.

One well-known example is Lutetium-177 PSMA therapy.

It is used for selected patients with advanced prostate cancer whose cancer expresses PSMA and who meet the relevant treatment criteria.

The radioactive medicine travels through the bloodstream and delivers radiation to PSMA-expressing cancer cells.

This is fundamentally different from external beam radiation.

Radiation is delivered from outside the body.

A radioactive medicine is administered into the body and travels to target sites.

Radiopharmaceutical therapy is generally considered for selected advanced cancers rather than as a routine first-line treatment for newly diagnosed low-risk prostate cancer. The NCI lists radiopharmaceutical therapy among treatments used for recurrent or advanced prostate cancer.

Related: Lutetium-177 PSMA Therapy in India.

Cryotherapy uses extreme cold to destroy prostate tissue containing cancer cells.

It is sometimes described as a minimally invasive or ablative treatment.

Cryotherapy can be used in selected circumstances, including certain recurrent cancers after radiation.

Some centres also offer it as a primary treatment for selected localized cancers.

However, its position is different from established surgery and radiation.

The American Cancer Society notes that most expert groups do not currently recommend ablative therapies such as cryotherapy as the first treatment when surgery and radiation are suitable, largely because long-term evidence is less mature.

High-intensity focused ultrasound (HIFU) uses concentrated ultrasound energy to heat and destroy targeted prostate tissue.

It may be delivered as:

The potential attraction is that it can target cancer while attempting to preserve more surrounding tissue.

However, HIFU is not equivalent to established radiation or surgery in terms of the maturity of long-term evidence.

The American Cancer Society notes that HIFU and other focal ablative approaches may be considered in selected situations but are generally not recommended as the first treatment when surgery or radiation are appropriate because long-term evidence remains more limited.

Focal therapy aims to treat the known cancer focus rather than treating the entire prostate.

Possible technologies include:

The concept is attractive because it attempts to preserve more normal prostate tissue.

However, patient selection is critical.

Focal therapy may not be suitable when:

Focal therapy should therefore not be presented as a universal replacement for surgery or radiation.

The appropriate treatment depends on the patient's specific disease characteristics rather than simply whether they want to avoid surgery.

One of the most useful ways to understand non-surgical treatment is by risk group.

For very low-risk disease, immediate treatment may not be necessary.

Active surveillance is commonly recommended.

The objective is to avoid exposing a slow-growing cancer to treatment side effects when the cancer may never become clinically significant.

Radiation remains an option for some men who prefer definitive treatment.

Active surveillance remains an important option.

Radiation therapy may also be used.

Possible radiation approaches include:

The choice depends on prostate anatomy, urinary symptoms, patient preferences and radiation-centre expertise.

This group requires more careful assessment.

Some men may still qualify for active surveillance.

Others may choose:

The decision depends on the specific Grade Group, PSA, tumour volume and other clinical factors.

The American Cancer Society includes active surveillance, radiation and surgery among potential options for selected favorable intermediate-risk disease.

Active surveillance becomes less commonly appropriate.

Non-surgical treatment may involve:

External beam radiation + hormone therapy

or, in selected cases:

External beam radiation + brachytherapy ± hormone therapy

The exact combination depends on the risk characteristics and treatment plan.

High-risk prostate cancer generally requires a more aggressive treatment strategy.

Non-surgical treatment commonly involves radiation combined with hormone therapy.

Radiation may include:

Longer-duration hormone therapy may be recommended for appropriate high-risk disease.

The American Cancer Society describes radiation combined with hormone therapy as an important treatment option for high- and very-high-risk disease.

Locally advanced prostate cancer has extended beyond the prostate but has not necessarily spread to distant organs.

Treatment can involve multiple modalities.

For selected patients, radiation plus hormone therapy can provide a non-surgical treatment pathway.

Systemic therapy may be intensified depending on the disease characteristics.

The treatment plan should therefore be developed by a multidisciplinary team involving urology, radiation oncology and medical oncology where appropriate.

When prostate cancer has spread to distant organs or bones, treatment is generally systemic.

Surgery is not usually the main treatment for controlling the entire disease.

Treatment may include:

The NCI lists hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, targeted treatments and other approaches depending on the disease setting.

Yes, radiation can be used with curative intent for appropriately selected localized prostate cancer.

This is an important distinction.

Radiation is not simply a treatment for patients who are “too old” or “too sick” for surgery.

For many men with localized prostate cancer, radiation is an established definitive treatment option.

The American Cancer Society notes that external radiation can be used as the initial treatment for prostate cancer confined to the prostate, with outcomes for selected early-stage disease comparable to those achieved with radical prostatectomy.

Both can be definitive treatments.

The choice involves more than cancer control.

Doctors and patients may also consider:

Long-term comparisons have shown that surgery and external radiation can provide similar survival outcomes in appropriately selected men with early-stage prostate cancer, while their side-effect profiles differ.

This is why the question should not simply be:

“Which treatment is better?”

A more useful question is:

“Which treatment is appropriate for my cancer and fits my priorities?”

The treatment-options guide compares surgery and radiation in more detail, including hospital stay and typical side-effect patterns.

Avoiding surgery does not mean avoiding side effects.

Every treatment has its own risk profile.

Possible concerns include:

Possible side effects include:

Some side effects improve after treatment, while others can persist.

Possible effects include:

The duration of hormone therapy influences the burden of some side effects.

Possible effects depend on the drug and treatment regimen and may include:

Possible complications include:

The risk depends on the technique and whether the entire prostate or only part of it is treated.

Yes.

Several established approaches leave the prostate in place.

The most important include:

However, leaving the prostate in place does not automatically mean that treatment is less aggressive.

Radiation, for example, can be definitive cancer treatment.

Yes.

Age alone should not determine treatment.

Doctors also consider:

An otherwise healthy older man with aggressive prostate cancer may benefit from active treatment.

Conversely, a younger man with a very low-risk tumour may appropriately choose active surveillance.

The American Cancer Society specifically notes that chronological age alone should not be the only factor when considering treatment choices.

Sometimes.

Patients with significant cardiovascular, respiratory or other medical conditions may face higher risks from major surgery.

Depending on the cancer, radiation, active surveillance, observation or systemic treatment may provide alternatives.

The decision should be based on both:

Cancer risk + overall medical risk.

This is particularly important for older patients.

Sometimes.

The treatment depends heavily on what was used initially.

Radiation therapy may be considered if PSA begins to rise or cancer recurrence is suspected.

Options can include selected salvage treatments such as:

However, salvage treatment after radiation can carry higher complication risks.

The American Cancer Society notes that treatment options after recurrence depend on the initial treatment and location of recurrent disease.

A doctor usually needs enough information to determine the cancer's risk and extent.

This may include:

PSA helps assess disease burden and monitor treatment response.

The biopsy establishes the diagnosis and provides:

Multiparametric MRI can help assess:

For selected patients, PSMA PET/CT can provide additional information about lymph-node or distant disease. Related: PSMA PET/CT for Prostate Cancer.

CT, bone imaging or other investigations may be used depending on the clinical situation.

Not every patient requires every test.

The Gleason score describes the microscopic appearance of prostate cancer.

It is converted into a Grade Group from 1 to 5.

In broad terms:

The Grade Group helps doctors determine how aggressively the cancer may behave.

That information influences whether active surveillance, radiation, surgery or systemic treatment should be considered.

A common mistake is to look at the PSA number alone.

PSA is important, but it does not tell the entire story.

Two men with similar PSA levels may have very different cancers.

Doctors also consider:

The treatment decision should therefore be based on the complete clinical picture.

There is currently no established diet, supplement or natural remedy that can replace evidence-based prostate cancer treatment.

A healthy diet, physical activity and maintaining a healthy weight can be useful for general health.

But they should not be presented as a substitute for:

Patients considering supplements should also discuss them with their medical team because some supplements can interact with medicines.

Sometimes.

The answer depends heavily on the risk group.

Possible approaches include:

Active surveillance may allow a patient to avoid both surgery and radiation.

Observation may be appropriate.

Hormone therapy and other systemic treatments can be used without prostate surgery or definitive prostate radiation in selected situations.

However, avoiding both surgery and radiation is not necessarily the goal.

The goal is to select treatment appropriate to the cancer and the patient's overall circumstances.

Yes.

Major Indian cancer centres offer several non-surgical treatment options, including:

Availability varies between hospitals.

International patients should confirm that the specific treatment required is available before travelling. Compare hospitals in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad.

Patients travelling to India can make the evaluation process easier by sending their medical records before arrival.

Useful documents include:

Hospitals may request additional tests after reviewing the records.

For international patients, a pre-arrival review can help clarify:

The decision usually follows a sequence.

The pathology report establishes that prostate cancer is present.

The biopsy indicates how aggressive the cancer appears.

Imaging determines whether the cancer is:

The doctor combines PSA, Grade Group and clinical stage.

Age, other medical conditions and life expectancy matter.

The patient may prioritize:

The final treatment plan may involve one modality or a combination.

This is an important point for patients searching online.

A patient may think:

“If I don't have surgery, I won't need much treatment.”

That is not necessarily true.

A man with high-risk prostate cancer may avoid surgery but still require:

Radiation + long-term hormone therapy + additional systemic treatment

That can represent a substantial treatment programme.

Likewise, a patient with low-risk cancer may avoid surgery because active surveillance is appropriate, meaning no immediate cancer-directed treatment is needed.

The difference comes from the biology and stage of the cancer.

Avoiding surgery is not always medically appropriate.

Surgery may remain a reasonable option when:

For selected localized cancers, surgery and radiation are both established definitive treatments.

The decision should be individualized rather than based solely on the desire to avoid an operation.

Related: Robotic Prostatectomy in India and radical prostatectomy cost.

If avoiding prostatectomy is important to you, ask:

These questions can make a consultation much more useful.

This is a framework, not a treatment recommendation for an individual patient.

Yes. Depending on the stage and risk group, treatment may include active surveillance, radiation therapy, hormone therapy, chemotherapy, targeted therapy, radiopharmaceutical therapy or selected ablative treatments.

There is no single non-surgical treatment that is appropriate for everyone. For localized disease, radiation may be a definitive treatment, while active surveillance may be appropriate for selected low-risk cancers. Advanced disease may require systemic treatment.

For appropriately selected localized prostate cancer, radiation can be used as definitive treatment with curative intent.

Yes. Active surveillance is commonly used for very-low- and low-risk disease, while radiation and brachytherapy are also options for selected patients.

Yes. Depending on the risk group, external beam radiation or brachytherapy may be used. Active surveillance may also be considered for selected lower-risk disease.

Yes. Radiation combined with hormone therapy is an important non-surgical treatment pathway for selected locally advanced or high-risk disease.

Yes. Stage IV prostate cancer is usually managed primarily with systemic treatment rather than prostate removal. Treatment may include hormone therapy, newer hormonal drugs, chemotherapy, targeted therapy, radiopharmaceutical therapy and radiation for selected symptoms or sites of disease.

Hormone therapy can control prostate cancer and may be an important part of treatment, particularly in advanced disease. It is not generally used alone as the definitive treatment for localized early-stage disease.

Not universally. HIFU is an option for selected patients, but long-term evidence is less mature than for established treatments such as surgery and radiation.

Cryotherapy may be appropriate in selected cases, including some recurrent cancers. It is not considered a universal replacement for surgery or radiation.

Yes. Active surveillance is specifically designed for selected cancers where immediate treatment may not be necessary.

For appropriately selected low-risk prostate cancer, active surveillance is an established management strategy. It requires regular monitoring so that treatment can begin if the cancer shows evidence of progression.

No. Some men eventually require treatment because their cancer changes or is found to be more aggressive than initially thought. Others remain on surveillance for many years.

Yes. Recurrence is possible after any definitive treatment. PSA monitoring is therefore an important part of follow-up.

Salvage surgery can sometimes be considered after radiation, but it is more technically difficult and carries higher risks of complications. The decision requires specialist assessment.

Not necessarily. Radiation, hormone therapy and other treatments have their own side effects. The relevant comparison is the type, likelihood and duration of side effects.

No established diet or natural remedy has been shown to replace evidence-based prostate cancer treatment.

A second opinion can be useful, particularly when several reasonable treatment options exist or when the recommended treatment would have significant long-term effects.

Prostate cancer does not always require surgery.

Depending on the cancer's risk and stage, non-surgical management may include:

The most important distinction is between monitoring the cancer and actively treating it without surgery.

For low-risk disease, active surveillance may allow some men to avoid treatment for years.

For localized disease that requires definitive treatment, radiation can treat the prostate without removing it.

For high-risk or metastatic disease, non-surgical treatment often involves combinations of radiation and systemic therapy.

The right approach depends on the patient's PSA, Grade Group, Gleason score, stage, imaging, overall health and treatment priorities.

If you are researching treatment in India, these related guides can help:

The primary internal link remains the main Prostate Cancer Treatment in India page. Supporting articles should link back to that page while maintaining their own specific search intent.

GAF Healthcare coordinates international patients who want prostate cancer treatment in India without assuming surgery is required. Share PSA reports, biopsy and Grade Group, MRI or PSMA PET, and previous treatment records. A coordinator can arrange specialist review, an itemized estimate and travel planning. The treating uro-oncology, radiation or medical oncology team makes the final recommendation.

This article is intended for general educational purposes and should not replace advice from a qualified urologist, radiation oncologist or medical oncologist.

Treatment decisions depend on the individual's pathology, PSA, Grade Group, stage, imaging, overall health and personal circumstances. Treatment availability and clinical recommendations can also vary between patients and hospitals.

1. National Cancer Institute — Prostate Cancer Treatment (PDQ) — surgery, radiation, hormone therapy, chemotherapy, targeted therapy and other treatments.

2. American Cancer Society — Initial Treatment Options for Prostate Cancer by Stage and Risk Group — how options vary by stage and risk group.

3. American Cancer Society — Radiation Therapy for Prostate Cancer — external beam radiation and brachytherapy.

4. American Cancer Society — Active Surveillance and Watchful Waiting — observation versus structured surveillance.

5. American Cancer Society — Cryotherapy, HIFU and Other Ablative Treatments — when ablative treatments may be considered.

Last reviewed against the cited sources: September 2026.